Latest news
Mesoblast’s Ryoncil Posts $115M First-Year Revenue on Pediatric Approval - The Clinical Trial VanguardThe Clinical Trial Vanguard · Mon, 03 Aug 2026 06:38:08 GMTMesoblast (ASX:MSB) Is Back in Focus After RYONCIL Revenue Reaches US$115 Million - KalkineKalkine · Thu, 30 Jul 2026 07:00:00 GMTMesoblast posts $36M Ryoncil revenue in Q4, holds $103M cash - scanx.tradescanx.trade · Thu, 30 Jul 2026 07:00:00 GMTMesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch - The Manila TimesThe Manila Times · Thu, 30 Jul 2026 01:15:08 GMTMesoblast reports $115M Ryoncil revenue in firs... - PluangPluang · Thu, 30 Jul 2026 01:11:43 GMTMesoblast reports $115M revenue in first year p... - PluangPluang · Thu, 30 Jul 2026 01:11:42 GMTMesoblast (ASX:MSB) Completes Phase 3 Back-Pain Enrolment as Ryoncil Growth and Pipeline Expansion Shape Next Phase - KalkineKalkine · Tue, 28 Jul 2026 13:11:00 GMTMesoblast Slips Even as Ryoncil Delivers Its First Full Year of Revenue - KalkineKalkine · Tue, 28 Jul 2026 12:42:00 GMT